Research analysts at Cowen and Company started coverage on shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a note issued to investors on Thursday. The brokerage set an “outperform” rating and a $64.00 price target on the biopharmaceutical company’s stock. Cowen and Company’s price target would suggest a potential upside of 27.01% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. UBS AG reiterated a “buy” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and reduced their price objective for the company from $85.00 to $55.00 in a research note on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price objective (up previously from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Northland Securities assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, August 29th. They issued an “outperform” rating and a $72.00 price objective for the company. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $52.54.

Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 50.39 on Thursday. The stock’s 50 day moving average is $47.73 and its 200-day moving average is $39.46. Esperion Therapeutics has a 1-year low of $9.40 and a 1-year high of $57.38. The stock’s market cap is $1.14 billion.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the business posted ($0.62) EPS. On average, analysts predict that Esperion Therapeutics will post ($7.29) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/10/cowen-and-company-initiates-coverage-on-esperion-therapeutics-inc-espr.html.

Large investors have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new position in Esperion Therapeutics during the 1st quarter valued at about $158,000. Tower Research Capital LLC TRC increased its holdings in Esperion Therapeutics by 69,371.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares in the last quarter. Aperio Group LLC purchased a new position in Esperion Therapeutics during the 2nd quarter valued at about $249,000. Princeton Alpha Management LP purchased a new position in Esperion Therapeutics during the 1st quarter valued at about $205,000. Finally, Bank of Montreal Can increased its holdings in Esperion Therapeutics by 1,006.7% during the 1st quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 83.33% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.